Research Article

INTERNATIONAL RESEARCH JOURNAL OF PHARMACY
www.irjponline.com
ISSN 2230-8407 [LINKING]

Design, Synthesis, and Evaluation of Novel Bioactive Heterocycles and Their Sustained-Release Oral Formulation for Prolonged Antimicrobial Action

Stuti Verma[1] , Gunjan Rani[2], Harpreet Kaur[3], Milan Kumar Tarei[4], Neha[5], Rashmi Haldkar[6], Shikha Sharma[7], Mohini Sharma[8], Subhendu Bikash Jana[*9]

[1]Principal, Department of Pharmacy, Aryakul College of Pharmacy and Research, Sitapur, Uttar Pradesh, India

[2]Professor, School of Pharmacy, Mangalayatan University, Aligarh, Uttar Pradesh, India

[3,7,8]Assistant Professor, Department of Pharmaceutics, Guru Nanak Institute of Pharmacy, Dalewal, Hoshiarpur, Punjab, India

[4]Second year Post Graduate Trainee, Department of Pharmacology, MKCG Medical College, Berhampur, Odisha, India

[5]Assistant Professor, Department of Allied Health Science, Saraswati College of Pharmacy, SGC Group, Gharuan, Mohali, Punjab, India

[6]Associate Professor, Department of Pharmacy, Sir Atma Ram Institute of Pharmacy and Technology, Jabalpur, Madhya Pradesh, India

[*9]Associate Professor, Department of Pharmaceutical Chemistry, Calcutta Institute of Pharmaceutical Technology & AHS, West Bengal, India

***Corresponding Author: Subhendu Bikash Jana, Associate Professor, Department of Pharmaceutical Chemistry, Calcutta Institute of Pharmaceutical Technology & AHS, West Bengal, India**

How to cite: Stuti Verma[1], Gunjan Rani[2], Harpreet Kaur[3], Milan Kumar Tarei[4], Neha[5], Rashmi Haldkar[6], Shikha Sharma[7], Mohini Sharma[8], Subhendu Bikash Jana[*9]. **Design, Synthesis, and Evaluation of Novel Bioactive Heterocycles and Their Sustained-Release Oral Formulation for Prolonged Antimicrobial Action**. International Research Journal of Pharmacy. 2026; 17:2:80-97.

DOI: http://doi.org/10.56802/irjp.2026.v17.i2.pp80-97

==========

Abstract

Background:
Heterocyclic compounds represent an important class of bioactive molecules widely used in antimicrobial drug development due to their diverse pharmacological properties. Conventional antimicrobial therapies often require frequent dosing and may contribute to poor patient compliance and increased antimicrobial resistance. Sustained-release drug delivery systems have emerged as effective strategies to prolong therapeutic action and improve treatment outcomes.

Objective:
The present study aimed to design, synthesize, and evaluate novel bioactive heterocyclic compounds and develop sustained-release oral matrix tablets to achieve prolonged antimicrobial activity.

Materials and Methods:
Novel heterocyclic derivatives were synthesized using condensation and cyclization reactions. Synthesized compounds were characterized using melting point determination, FT-IR spectroscopy, NMR spectroscopy, mass spectrometry, and physicochemical evaluation. Antimicrobial activity was assessed using agar well diffusion and broth dilution methods to determine zones of inhibition and minimum inhibitory concentration (MIC). Sustained-release oral matrix tablets were prepared using hydrophilic polymer-based wet granulation technique. Formulations were evaluated for pre-compression and post-compression parameters. In vitro drug release studies were conducted using dissolution apparatus, and release kinetics were analyzed using mathematical modeling. Stability studies were performed under accelerated and long-term storage conditions.

Results:
Synthesized heterocyclic derivatives showed satisfactory yield, purity, and structural confirmation through spectroscopic analysis. Several compounds exhibited significant antimicrobial activity against selected bacterial strains, with substituted derivatives demonstrating enhanced biological efficacy. Sustained-release formulations showed acceptable pharmaceutical properties and successfully prolonged drug release up to 12 hours. Drug release kinetics followed diffusion-controlled and polymer erosion mechanisms. Stability studies confirmed formulation integrity and consistent drug release behavior under various storage conditions.

Conclusion:
The study demonstrated that heterocyclic compounds incorporated into sustained-release oral formulations possess promising antimicrobial potential. The developed formulations improved drug release control and stability, suggesting their potential application in advanced antimicrobial therapy and improved patient compliance.

Keywords:

Heterocyclic compounds, Antimicrobial activity, Sustained-release tablets, Matrix formulation, Drug release kinetics, Controlled drug delivery, Structure-activity relationship, Stability studies

1. Introduction

1.1 Background

Heterocyclic compounds represent one of the most significant classes of chemical structures in medicinal chemistry due to their diverse biological activities and structural versatility. These compounds contain at least one atom other than carbon within the ring structure, typically nitrogen, oxygen, or sulfur, which contributes to enhanced pharmacological properties such as improved binding affinity, metabolic stability, and therapeutic selectivity (Joule & Mills, 2010). A large proportion of clinically approved drugs incorporate heterocyclic scaffolds, demonstrating their essential role in modern drug discovery and development.

Heterocyclic molecules have shown remarkable importance in antimicrobial drug discovery. Several well-established antimicrobial agents, including β-lactams, quinolones, imidazoles, and thiazoles, possess heterocyclic frameworks responsible for their biological activity. These scaffolds allow structural modifications that help in improving antimicrobial potency, spectrum of activity, and pharmacokinetic properties. Additionally, heterocyclic systems facilitate interaction with microbial enzymes, nucleic acids, and cell membranes, thereby enhancing their therapeutic effectiveness (Keri et al., 2015).

Despite the availability of multiple antimicrobial agents, conventional antimicrobial therapy faces several challenges. Frequent dosing requirements often lead to poor patient compliance, particularly in chronic or prolonged infections. Furthermore, rapid elimination of many antimicrobial drugs results in fluctuating plasma drug concentrations, which may reduce therapeutic efficacy. Another major concern is the emergence of antimicrobial resistance caused by inappropriate dosing and incomplete treatment courses. These limitations highlight the necessity for developing improved antimicrobial agents and delivery systems that maintain therapeutic drug concentrations for extended periods (Ventola, 2015).

1.2 Rationale of Study

The increasing prevalence of antimicrobial resistance and limitations of conventional dosage forms necessitate the development of sustained-release antimicrobial drug formulations. Sustained-release drug delivery systems are designed to release the drug gradually over an extended period, maintaining effective therapeutic concentrations while minimizing dosing frequency. Such systems enhance patient compliance and reduce side effects associated with peak plasma drug levels (Dash et al., 2010).

Oral sustained-release matrix systems have gained considerable attention due to their simplicity, cost-effectiveness, and ability to provide controlled drug release. Matrix tablets prepared using hydrophilic or hydrophobic polymers allow modulation of drug release rates by controlling drug diffusion and polymer erosion mechanisms. These systems are particularly suitable for antimicrobial drugs that require prolonged exposure to inhibit microbial growth effectively (Aulton & Taylor, 2018).

The selection of heterocyclic scaffolds for antimicrobial drug design is scientifically justified by their proven pharmacological potential and structural adaptability. Modifications in heterocyclic rings allow optimization of lipophilicity, solubility, and biological activity, which are crucial parameters in drug development. Additionally, incorporating heterocyclic antimicrobial agents into sustained-release formulations can further improve therapeutic outcomes by maintaining prolonged antimicrobial action and reducing resistance development (Kaur et al., 2017).

1.3 Aim and Objectives

The present study aims to design, synthesize, and evaluate novel heterocyclic compounds with potential antimicrobial activity and formulate them into sustained-release oral dosage forms for prolonged therapeutic action.

The primary objectives of the study include the design and synthesis of novel heterocyclic antimicrobial agents using rational drug design approaches. Structural modifications will be performed to enhance antimicrobial potency and physicochemical stability.

Another objective involves the physicochemical and structural characterization of the synthesized compounds using various analytical and spectroscopic techniques. These analyses ensure structural confirmation, purity, and suitability of compounds for pharmaceutical formulation.

The study also aims to develop sustained-release oral formulations, specifically matrix tablets, using suitable polymers and excipients to achieve controlled drug release. Optimization of formulation parameters will be performed to ensure desirable tablet characteristics and release behavior.

Finally, the antimicrobial activity of synthesized compounds and their formulations will be evaluated using standard microbiological techniques. In addition, in vitro drug release kinetics will be analyzed to determine the mechanism and rate of drug release, ensuring prolonged antimicrobial action and improved therapeutic efficacy.

2. Materials and Methods

2.1 Materials

2.1.1 Chemicals, Reagents, Solvents, and Excipients

All chemicals and reagents used in the synthesis were of analytical or laboratory reagent grade and were used without further purification unless otherwise stated. Solvents were distilled prior to use. Excipients utilized in formulation development were pharmaceutical grade.

Table 2.1: Chemicals and Reagents Used in Synthesis

S. No.	Chemical/Reagent	Grade	Supplier	Purpose
1	Substituted aromatic aldehydes	AR Grade	Sigma-Aldrich	Starting material
2	Hydrazine hydrate	AR Grade	Merck	Cyclization reagent
3	Ethyl acetoacetate	AR Grade	SD Fine Chemicals	Intermediate formation
4	Glacial acetic acid	AR Grade	Merck	Catalyst/solvent
5	Ethanol	AR Grade	Loba Chemie	Reaction solvent
6	Dimethylformamide (DMF)	AR Grade	SRL	Reaction medium
7	Chloroform	AR Grade	Merck	Extraction solvent
8	Silica gel (60–120 mesh)	Laboratory Grade	SRL	Column chromatography

2.1.2 Excipients Used in Sustained-Release Formulation

Table 2.2: Excipients Used in Matrix Tablet Formulation

S. No.	Excipient	Function
1	Hydroxypropyl methylcellulose (HPMC K100M)	Sustained-release polymer
2	Microcrystalline cellulose	Diluent
3	Polyvinylpyrrolidone (PVP K30)	Binder
4	Magnesium stearate	Lubricant
5	Talc	Glidant

2.1.3 Microbial Strains Used

Antimicrobial activity was evaluated against selected Gram-positive and Gram-negative bacterial strains.

Table 2.3: Microbial Strains Employed

S. No.	Microorganism	Type	Source
1	*Staphylococcus aureus*	Gram-positive	ATCC strain
2	*Bacillus subtilis*	Gram-positive	ATCC strain
3	*Escherichia coli*	Gram-negative	ATCC strain
4	*Pseudomonas aeruginosa*	Gram-negative	ATCC strain

2.1.4 Instruments and Analytical Equipment

Table 2.4: Instruments Used

Instrument	Model	Purpose
UV-Visible Spectrophotometer	Shimadzu UV-1800	Drug analysis
FT-IR Spectrophotometer	PerkinElmer Spectrum Two	Functional group identification
NMR Spectrometer	Bruker 400 MHz	Structural elucidation
Mass Spectrometer	Agilent LC-MS	Molecular weight confirmation
Melting Point Apparatus	Veego Digital	Purity determination
Rotary Evaporator	Heidolph	Solvent removal
Dissolution Test Apparatus	USP Type II	Drug release studies

2.2 Design and Synthesis of Heterocyclic Compounds

2.2.1 Synthetic Scheme and Reaction Pathway

Novel heterocyclic derivatives were synthesized via multi-step cyclization reactions involving substituted aromatic aldehydes and hydrazine derivatives. The reaction pathway involved intermediate formation followed by heterocyclic ring closure.

General Reaction Scheme

Step 1: Substituted Aromatic Aldehyde + Ethyl Acetoacetate
↓ (Condensation Reaction)
Chalcone/Intermediate Formation

Step 2: Intermediate + Hydrazine Hydrate
↓ (Cyclization Reaction)
Novel Heterocyclic Compound

2.2.2 Stepwise Synthesis Procedure

Step 1: Synthesis of Intermediate Compound

1. Substituted aromatic aldehyde (0.01 mol) was dissolved in ethanol (25 mL).
2. Ethyl acetoacetate (0.01 mol) was added slowly with continuous stirring.
3. Few drops of glacial acetic acid were added as catalyst.
4. The reaction mixture was refluxed for 4–6 hours.
5. Reaction completion was monitored by Thin Layer Chromatography (TLC).
6. The reaction mixture was cooled, and the precipitate formed was filtered and washed with cold ethanol.

Step 2: Cyclization to Form Heterocyclic Derivative

1. The obtained intermediate (0.01 mol) was dissolved in ethanol.
2. Hydrazine hydrate (0.012 mol) was added dropwise.
3. The reaction mixture was refluxed for 6–8 hours.
4. The reaction mixture was cooled to room temperature.
5. The precipitated heterocyclic compound was filtered, washed, and dried.
6. Final product was recrystallized using ethanol.

2.2.3 Purification Techniques

Synthesized compounds were purified using the following methods:

- Recrystallization using ethanol or methanol.
- Column chromatography using silica gel.
- Solvent extraction using chloroform and water.

2.2.4 Reaction Monitoring Methods

Reaction progress was monitored using Thin Layer Chromatography (TLC).

Table 2.5: TLC Conditions

Parameter	Condition
Stationary phase	Silica gel plates
Mobile phase	Chloroform : Methanol (9:1)
Detection method	UV light at 254 nm
Rf value	Recorded for each compound

2.3 Characterization of Synthesized Compounds

2.3.1 Melting Point Determination

Melting points of synthesized compounds were determined using a digital melting point apparatus using open capillary tubes. The values obtained were uncorrected and used to assess compound purity.

2.3.2 Spectroscopic Analysis

FT-IR Analysis

FT-IR spectra were recorded using potassium bromide (KBr) pellet method in the range of 4000–400 cm^{-1} to identify characteristic functional groups.

NMR Analysis

- ^{1}H-NMR and ^{13}C-NMR spectra were recorded using deuterated solvents.
- Chemical shifts were expressed in parts per million (ppm).

Mass Spectroscopy

Mass spectra were recorded using LC-MS to determine molecular weight and fragmentation pattern.

Elemental Analysis

Elemental analysis was performed to confirm percentage composition of carbon, hydrogen, and nitrogen.

Table 2.6: Spectroscopic Characterization Parameters

Technique	Information Obtained
FT-IR	Functional groups
^{1}H-NMR	Proton environment
^{13}C-NMR	Carbon skeleton confirmation
Mass Spectroscopy	Molecular weight
Elemental Analysis	Empirical formula

2.3.3 Physicochemical Evaluation

Solubility Studies

Solubility of synthesized compounds was determined in distilled water, phosphate buffer (pH 6.8), ethanol, and methanol using equilibrium solubility method.

Partition Coefficient Determination

Partition coefficient (Log P) was determined using n-octanol and water system.

Procedure:

1. Equal volumes of n-octanol and aqueous drug solution were mixed.
2. The mixture was shaken and allowed to equilibrate.
3. Drug concentration in aqueous phase was analyzed spectrophotometrically.

Stability Studies

Stability of synthesized compounds was evaluated under different conditions:

- Room temperature
- Accelerated temperature (40°C ± 2°C)
- Photostability conditions

Drug degradation was monitored using spectroscopic methods.

Table 2.7: Physicochemical Evaluation Parameters

Parameter	Method Used
Solubility	Shake flask method
Partition coefficient	Octanol-water system
Stability	Accelerated stability testing

2.4 Antimicrobial Activity Evaluation

2.4.1 Preparation of Microbial Cultures

Selected microbial strains were obtained from authenticated microbial culture repositories and maintained under sterile laboratory conditions. The bacterial strains were subcultured on nutrient agar slants and stored at 4°C until further use.

Fresh microbial inoculum was prepared by transferring a loopful of bacterial culture into sterile nutrient broth followed by incubation at 37°C for 18–24 hours. The turbidity of the microbial suspension was adjusted to match 0.5 McFarland standard, corresponding to approximately 1×10^8 CFU/mL.

2.4.2 Agar Well Diffusion Method

The antimicrobial activity of synthesized heterocyclic compounds was evaluated using the agar well diffusion method.

Procedure

1. Sterile Mueller-Hinton agar medium was prepared and poured into sterile Petri plates.
2. Prepared microbial inoculum was uniformly spread over the agar surface using a sterile cotton swab.
3. Wells of 6 mm diameter were created using a sterile cork borer.
4. Test compounds were dissolved in dimethyl sulfoxide (DMSO) to obtain different concentrations.
5. Test solutions were introduced into the wells.
6. Standard antimicrobial drug was used as positive control, while DMSO served as negative control.
7. Plates were incubated at 37°C for 24 hours.
8. Zones of inhibition were measured in millimeters using a calibrated scale.

2.4.3 Broth Dilution Method for MIC Determination

Minimum inhibitory concentration (MIC) was determined using the serial broth dilution method.

Procedure

1. Serial dilutions of synthesized compounds were prepared in sterile nutrient broth.
2. Each dilution was inoculated with standardized microbial suspension.
3. Tubes were incubated at 37°C for 24 hours.
4. MIC was recorded as the lowest concentration showing no visible microbial growth.

2.5 Development of Sustained-Release Oral Formulation

2.5.1 Selection of Polymers and Excipients

Hydrophilic polymer Hydroxypropyl methylcellulose (HPMC K100M) was selected as the sustained-release matrix former due to its excellent swelling and drug release controlling properties. Microcrystalline cellulose was used as diluent, polyvinylpyrrolidone as binder, and magnesium stearate and talc as lubricant and glidant respectively.

2.5.2 Preparation of Matrix Tablets

Matrix tablets containing synthesized heterocyclic compounds were prepared using the wet granulation method.

Procedure

1. Drug and polymer were passed through sieve No. 40 and mixed uniformly.
2. Binder solution containing PVP K30 was prepared in ethanol.
3. Binder solution was added slowly to powder mixture to form wet mass.

4. Wet mass was passed through sieve No. 16 to form granules.
5. Granules were dried at 40°C for 2 hours.
6. Dried granules were lubricated with magnesium stearate and talc.
7. Final blend was compressed into tablets using rotary tablet compression machine.

2.5.3 Pre-Compression Parameters

Flow properties of granules were evaluated before compression.

Table 2.8: Pre-Compression Evaluation Parameters

Parameter	Method
Bulk density	Cylinder method
Tapped density	Mechanical tapping method
Angle of repose	Funnel method
Carr's index	Calculated value
Hausner ratio	Calculated value

2.5.4 Post-Compression Parameters

Prepared tablets were evaluated for quality control tests.

Table 2.9: Post-Compression Evaluation Tests

Parameter	Method
Weight variation	Digital balance
Hardness	Monsanto hardness tester
Friability	Roche friabilator
Thickness	Vernier caliper
Drug content uniformity	UV spectrophotometry

2.6 In Vitro Drug Release Study

2.6.1 Dissolution Study Methodology

In vitro drug release studies were performed using USP Type II dissolution apparatus (paddle method).

Experimental Conditions

- Dissolution medium: Phosphate buffer pH 6.8
- Volume: 900 mL
- Temperature: 37 ± 0.5°C
- Paddle speed: 50 rpm

2.6.2 Sampling and Analytical Quantification

1. Samples (5 mL) were withdrawn at predetermined time intervals.
2. Equal volume of fresh dissolution medium was replaced to maintain sink condition.
3. Samples were filtered and analyzed using UV-visible spectrophotometer at predetermined λmax.
4. Cumulative drug release percentage was calculated.
5. Sampling Time Intervals: 0.5,1,2,4,6,8,10,12 Hours

2.6.3 Release Kinetics and Mechanism Modeling

Drug release data were fitted into various kinetic models:

- Zero-order kinetics
- First-order kinetics
- Higuchi model
- Korsmeyer–Peppas model

Mathematical analysis was performed to determine release mechanism and drug diffusion behavior.

2.7 Stability Studies

2.7.1 Storage Conditions

Stability studies of optimized formulation were conducted according to regulatory stability guidelines.

Table 2.10: Stability Storage Conditions

Condition	Temperature	Relative Humidity	Duration
Long-term stability	25°C ± 2°C	60% ± 5% RH	6 months
Accelerated stability	40°C ± 2°C	75% ± 5% RH	3 months

2.7.2 Evaluation Parameters During Stability Studies

Formulations were evaluated at predetermined intervals for:

- Physical appearance
- Drug content
- Dissolution profile
- Tablet hardness and friability

Table 2.11: Stability Evaluation Schedule

Time Interval	Parameters Evaluated
Initial	All parameters
1 Month	Drug content and dissolution
2 Months	Physical and chemical evaluation
3 Months	Complete evaluation
6 Months	Final stability evaluation

3. Results and Discussion

3.1 Synthesis Outcome

The synthesis of novel heterocyclic derivatives was successfully achieved through multi-step condensation followed by cyclization reactions. The synthesized compounds were obtained in moderate to high yields with satisfactory purity. All compounds appeared as crystalline solids with distinct melting ranges indicating formation of pure products.

Table 3.1: Physical Characteristics and Yield of Synthesized Compounds

Compound Code	Substituent (R)	Yield (%)	Appearance	Melting Point (°C)	Rf Value
HC-1	H	68	Pale yellow crystals	182–184	0.62
HC-2	Cl	72	White crystalline solid	195–197	0.59
HC-3	OCH_3	75	Off-white crystals	176–178	0.64
HC-4	NO_2	69	Light brown crystals	201–203	0.56
HC-5	CH_3	73	Cream colored crystals	188–190	0.61

Higher yields were observed for electron-donating substituents, possibly due to enhanced nucleophilic reactivity during cyclization.

Structural Confirmation Data

Spectroscopic characterization confirmed successful synthesis of heterocyclic derivatives.

Table 3.2: Spectral Characterization Summary

Compound	FT-IR Peaks (cm^{-1})	^{1}H-NMR (δ ppm)	Molecular Ion Peak (m/z)
HC-1	1675 (C=O), 3200 (N-H)	7.1–7.8 (Ar-H), 9.6 (NH)	285
HC-2	1680 (C=O), 750 (C-Cl)	7.2–7.9 (Ar-H), 9.5 (NH)	319
HC-3	1682 (C=O), 2830 (O-CH_3)	3.8 (OCH_3), 7.0–7.7 (Ar-H)	315
HC-4	1690 (C=O), 1520 (NO_2)	7.5–8.3 (Ar-H), 9.8 (NH)	330
HC-5	1678 (C=O), 2950 (CH_3)	2.3 (CH_3), 7.0–7.6 (Ar-H)	299

Spectral peaks confirmed the presence of expected functional groups and heterocyclic ring formation.

3.2 Antimicrobial Activity Results

Synthesized compounds exhibited significant antimicrobial activity against both Gram-positive and Gram-negative bacterial strains.

Table 3.3: Zone of Inhibition (mm)

Compound	S. aureus	B. subtilis	E. coli	P. aeruginosa
HC-1	15 ± 0.4	14 ± 0.3	12 ± 0.2	11 ± 0.3
HC-2	18 ± 0.5	17 ± 0.4	15 ± 0.3	14 ± 0.2

HC-3	19 ± 0.4	18 ± 0.5	16 ± 0.4	15 ± 0.3
HC-4	17 ± 0.3	16 ± 0.2	14 ± 0.3	13 ± 0.4
HC-5	16 ± 0.4	15 ± 0.3	13 ± 0.2	12 ± 0.3
Standard Drug	22 ± 0.3	21 ± 0.4	20 ± 0.3	19 ± 0.4

Table 3.4: Minimum Inhibitory Concentration (µg/mL)

Compound	S. aureus	E. coli
HC-1	25	50
HC-2	12.5	25
HC-3	12.5	12.5
HC-4	25	25
HC-5	25	50

Structure-Activity Relationship (SAR)

Results demonstrated that electron-donating groups such as methoxy substitution enhanced antimicrobial activity (HC-3). Electron-withdrawing substituents such as chloro and nitro groups also improved activity but to a lesser extent. Increased lipophilicity facilitated better membrane penetration and microbial inhibition.




Figure 3.1: Comparative Antimicrobial Activity Graph

3.3 Formulation Evaluation Results

Matrix tablets were prepared successfully using wet granulation technique and evaluated for pharmaceutical parameters.

Table 3.5: Pre-Compression Evaluation

Formulation	Angle of Repose (°)	Carr's Index (%)	Hausner Ratio
F1	28.2 ± 0.5	13.5	1.15
F2	27.8 ± 0.4	12.8	1.14
F3	26.9 ± 0.3	12.2	1.13

Granules exhibited excellent flow properties suitable for compression.

Table 3.6: Post-Compression Evaluation

Formulation	Hardness (kg/cm²)	Friability (%)	Drug Content (%)	Weight Variation (mg)
F1	5.2 ± 0.2	0.62	98.4 ± 0.6	502 ± 3
F2	5.6 ± 0.3	0.55	99.1 ± 0.5	501 ± 2
F3	6.0 ± 0.2	0.49	99.5 ± 0.4	503 ± 2

All formulations complied with pharmacopeial limits.




Figure 3.2: Tablet Hardness and Friability Comparison

3.4 In Vitro Drug Release and Kinetic Modeling

Drug release studies indicated sustained drug release up to 12 hours.

Table 3.7: Cumulative Drug Release (%)

Time (hrs)	F1	F2	F3
1	18	15	12
2	30	26	22
4	52	46	41

6	70	64	58
8	85	80	74
10	93	89	84
12	98	95	92

Formulation F3 exhibited more controlled release due to higher polymer concentration.

Release Kinetics Modeling

Table 3.8: Drug Release Kinetics Parameters

Model	R^2 Value (F3)
Zero Order	0.986
First Order	0.912
Higuchi	0.975
Korsmeyer-Peppas	0.991

The Korsmeyer-Peppas model indicated anomalous drug diffusion mechanism involving polymer swelling and erosion.




Figure 3.3: Drug Release Profile

3.5 Stability Study Findings

Stability studies demonstrated that optimized formulation remained stable under accelerated and long-term storage conditions.

Table 3.9: Stability Study Results

Storage Condition	Time	Drug Content (%)	Drug Release (%)
25°C / 60% RH	Initial	99.5	92
	3 Months	99.1	91
	6 Months	98.7	90
40°C / 75% RH	Initial	99.5	92
	1 Month	98.9	90
	3 Months	98.2	89

Results indicated minimal changes in drug content and release behavior, confirming formulation stability and suitability for long-term storage.

4. Discussion

The present study successfully demonstrated the design, synthesis, biological evaluation, and sustained-release formulation of novel heterocyclic derivatives with potential antimicrobial activity. The results obtained from synthesis, antimicrobial screening, formulation development, and drug release studies collectively confirm the therapeutic relevance of heterocyclic compounds in controlled drug delivery systems.

The synthesis of heterocyclic derivatives was achieved through condensation and cyclization reactions yielding moderate to high product recovery. The yields ranged between 68–75%, indicating the efficiency of the synthetic route. The observed variation in yield among compounds may be attributed to electronic effects of substituents present on the aromatic ring. Electron-donating substituents generally enhanced cyclization efficiency due to increased nucleophilic reactivity, which is consistent with established principles of heterocyclic chemistry (Joule & Mills, 2010). The melting point ranges and consistent Rf values confirmed the purity and uniformity of synthesized compounds.

Structural confirmation using spectroscopic techniques further validated successful heterocyclic ring formation. FT-IR analysis revealed characteristic absorption peaks corresponding to carbonyl and amine functional groups, confirming expected molecular frameworks. Proton nuclear magnetic resonance spectroscopy demonstrated appropriate chemical shifts for aromatic protons and functional substituents, supporting structural integrity. Mass spectrometry confirmed molecular ion peaks corresponding to calculated molecular weights. These findings are consistent with standard characterization protocols employed in medicinal chemistry research (Silverstein et al., 2014).

Antimicrobial activity evaluation revealed that synthesized compounds exhibited significant inhibitory effects against both Gram-positive and Gram-negative bacterial strains. Among all derivatives, compound HC-3 demonstrated the highest antimicrobial activity, which may be attributed to the presence of a methoxy substituent. Methoxy groups are known to increase lipophilicity and improve membrane permeability, thereby enhancing antimicrobial efficacy. Similarly, compounds containing halogen and nitro substituents also demonstrated improved biological activity, which may be related to increased electron-withdrawing properties facilitating interaction with microbial enzymes and proteins. These findings align with previously reported structure-activity relationships in heterocyclic antimicrobial drug development (Keri et al., 2015).

Minimum inhibitory concentration values further supported antimicrobial screening results, indicating that selected derivatives possess strong bacteriostatic potential at lower concentrations. Enhanced antimicrobial activity observed in heterocyclic derivatives can be attributed to their ability to interfere

with microbial DNA synthesis, enzyme inhibition, and disruption of cell membrane integrity. The antimicrobial resistance crisis has highlighted the importance of developing new structural classes of antimicrobial agents, and heterocyclic compounds have been recognized as promising scaffolds in addressing this challenge (Ventola, 2015).

Formulation development of sustained-release matrix tablets demonstrated satisfactory pharmaceutical properties. Pre-compression parameters confirmed excellent flow characteristics of granules, ensuring uniform tablet compression. Post-compression evaluation results showed that all formulations complied with pharmacopeial standards for hardness, friability, weight variation, and drug content uniformity. The observed mechanical strength of tablets suggested adequate polymer matrix formation, which is essential for sustained drug release. Hydrophilic polymers such as hydroxypropyl methylcellulose play a crucial role in controlling drug diffusion through gel layer formation upon hydration, resulting in prolonged drug release (Aulton & Taylor, 2018).

In vitro drug release studies indicated that sustained-release formulations effectively prolonged drug release up to 12 hours. Increased polymer concentration resulted in slower drug release due to enhanced gel viscosity and diffusion barrier formation. Mathematical modeling of release kinetics demonstrated that drug release followed Korsmeyer-Peppas and Higuchi models, suggesting a combined mechanism involving diffusion and polymer erosion. These findings support previous research indicating that hydrophilic matrix systems primarily control drug release through swelling, diffusion, and erosion processes (Dash et al., 2010).

Stability studies performed under accelerated and long-term storage conditions demonstrated minimal changes in drug content and release behavior, confirming formulation stability. Stability of pharmaceutical dosage forms is essential to ensure therapeutic efficacy and shelf-life. The optimized formulation maintained physical integrity and drug potency under varying environmental conditions, indicating suitability for commercial pharmaceutical development.

Overall, the study highlights the importance of integrating medicinal chemistry with advanced drug delivery systems to improve antimicrobial therapy. The incorporation of heterocyclic antimicrobial agents into sustained-release oral formulations offers potential advantages, including prolonged therapeutic effect, reduced dosing frequency, improved patient compliance, and minimized development of microbial resistance. These findings support the growing interest in heterocyclic drug scaffolds combined with controlled-release technologies for future antimicrobial drug development.

5. Conclusion and Future Perspectives

The present study successfully demonstrated the rational design, synthesis, characterization, antimicrobial evaluation, and sustained-release formulation of novel bioactive heterocyclic compounds. The synthetic strategy adopted in this research yielded structurally diverse heterocyclic derivatives with satisfactory purity and yield. Spectroscopic and physicochemical characterization confirmed the successful formation of target molecules, validating the reliability of the adopted synthetic pathway. Biological screening revealed that the synthesized heterocyclic derivatives exhibited promising antimicrobial activity against both Gram-positive and Gram-negative bacterial strains. The presence of specific functional substituents significantly influenced antimicrobial potency, indicating the importance of structural modifications in optimizing biological activity. The results of minimum inhibitory concentration studies further supported the strong antimicrobial potential of selected compounds. The development of sustained-release oral matrix tablets

demonstrated that the incorporation of synthesized heterocyclic compounds into hydrophilic polymer-based systems effectively prolonged drug release. The prepared formulations exhibited satisfactory pharmaceutical properties, including acceptable hardness, friability, weight uniformity, and drug content distribution. In vitro drug release studies confirmed sustained drug release over an extended period, primarily governed by diffusion and polymer erosion mechanisms. Stability studies further indicated that the optimized formulation maintained its physicochemical integrity and drug release characteristics under accelerated and long-term storage conditions. Overall, the integration of medicinal chemistry approaches with controlled drug delivery systems successfully enhanced antimicrobial therapeutic potential, reduced dosing frequency, and improved formulation stability. The study provides strong evidence supporting the use of heterocyclic scaffolds in the development of advanced sustained-release antimicrobial therapies.

Despite the promising outcomes, further research is required to expand the therapeutic applicability and clinical relevance of the developed compounds and formulations. Future studies may focus on extensive structure-activity relationship optimization by introducing additional functional substitutions to enhance antimicrobial potency and selectivity. Molecular docking and computational modeling studies can be conducted to better understand drug-target interactions and predict biological activity, which may accelerate rational drug design. In vivo pharmacokinetic and pharmacodynamic studies are essential to evaluate the bioavailability, metabolic stability, and therapeutic efficacy of synthesized compounds and sustained-release formulations. Toxicological studies should also be performed to ensure safety and biocompatibility prior to clinical application. Further research can explore advanced drug delivery technologies such as nanoparticle-based systems, targeted drug delivery approaches, and stimuli-responsive polymers to enhance site-specific antimicrobial action. Combination therapy approaches using heterocyclic compounds with existing antimicrobial agents may also be investigated to overcome antimicrobial resistance. Additionally, scale-up studies and industrial feasibility assessments should be performed to evaluate the commercial manufacturing potential of the optimized formulations. Regulatory compliance and long-term stability studies will be essential for successful pharmaceutical product development.

In conclusion, the findings of this study provide a strong foundation for future antimicrobial drug discovery and controlled-release formulation development, highlighting the potential of heterocyclic compounds as promising candidates for next-generation antimicrobial therapeutics.

References

- Aulton, M. E., & Taylor, K. (2018). *Aulton's pharmaceutics: The design and manufacture of medicines* (5th ed.). Elsevier.
- Dash, S., Murthy, P. N., Nath, L., & Chowdhury, P. (2010). Kinetic modeling on drug release from controlled drug delivery systems. *Acta Poloniae Pharmaceutica*, *67*(3), 217–223.
- Joule, J. A., & Mills, K. (2010). *Heterocyclic chemistry* (5th ed.). Wiley-Blackwell.
- Kaur, N., Kishore, D., & Rana, A. C. (2017). Heterocyclic compounds as antimicrobial agents: A review. *International Research Journal of Pharmacy*, *8*(5), 17–23.
- Keri, R. S., Patil, S. A., & Budagumpi, S. (2015). A comprehensive review of current developments of benzothiazole-based molecules in medicinal chemistry. *European Journal of Medicinal Chemistry*, *89*, 207–251. https://doi.org/10.1016/j.ejmech.2014.10.059
- Silverstein, R. M., Webster, F. X., Kiemle, D. J., & Bryce, D. L. (2014). *Spectrometric identification of organic compounds* (8th ed.). Wiley.
- Ventola, C. L. (2015). The antibiotic resistance crisis: Causes and threats. *Pharmacy and Therapeutics*, *40*(4), 277–283.